Quick Answer
Pacira BioSciences, Inc. reported Total Revenue of $726.41 million for fiscal year 2025.
Pacira BioSciences, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $726.41M +3.6% |
$700.97M +3.9% |
$674.98M +1.2% |
$666.82M +23.1% |
$541.53M +26.0% |
$429.65M +2.0% |
| Revenue (ASC 606) | $726.41M +3.6% |
$700.97M +3.9% |
$674.98M +1.2% |
$666.82M +23.1% |
$541.53M +26.0% |
$429.65M |
| Net Income | $7.03M +107.1% |
-$99.56M -337.3% |
$41.95M +163.7% |
$15.91M -62.1% |
$41.98M -71.2% |
$145.52M +1421.0% |
| Diluted EPS | $0.16 +107.4% |
-$2.15 -341.6% |
$0.89 +161.8% |
$0.34 -63.0% |
$0.92 -72.4% |
$3.33 +1333.3% |
| Total Assets | $1.26B -18.6% |
$1.55B -1.3% |
$1.57B -6.4% |
$1.68B -19.0% |
$2.08B +62.8% |
$1.27B +53.4% |
| Cash and Equivalents | $158.54M -42.7% |
$276.77M +80.5% |
$153.30M +47.2% |
$104.14M -82.2% |
$585.58M +485.8% |
$99.96M +27.8% |
| Long-Term Debt | $372.19M -3.0% |
$383.55M | — | — | — | — |
| Stockholders Equity | $693.11M -11.0% |
$778.35M -10.5% |
$870.13M +12.3% |
$775.01M +6.1% |
$730.41M +17.9% |
$619.69M +74.6% |
| R&D Expense | $117.31M +43.8% |
$81.58M +7.0% |
$76.26M -10.1% |
$84.80M +52.7% |
$55.55M -6.5% |
$59.42M -17.6% |
| Operating Income | $19.19M +126.2% |
-$73.37M -183.7% |
$87.67M +46.1% |
$60.02M -33.3% |
$89.92M +94.0% |
$46.35M +342.3% |
| Shares Outstanding | 41.12M -11.1% |
46.24M -0.5% |
46.48M +1.2% |
45.93M +2.7% |
44.73M +2.5% |
43.64M +4.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $179.52M | +6.5% | -0.9% |
| Revenue (ASC 606) | September 30, 2025 | $179.52M | +6.5% | -0.9% |
| Net Income | September 30, 2025 | $5.43M | +103.8% | +212.1% |
| Diluted EPS | September 30, 2025 | $0.12 | +103.9% | +209.1% |
| Total Assets | September 30, 2025 | $1.30B | -14.7% | -15.6% |
| Cash and Equivalents | September 30, 2025 | $147.59M | -40.0% | -50.9% |
| Long-Term Debt | September 30, 2025 | $376.72M | — | -1.8% |
| Stockholders Equity | September 30, 2025 | $727.21M | -3.0% | -4.0% |
| R&D Expense | September 30, 2025 | $25.97M | +35.9% | -7.9% |
| Operating Income | September 30, 2025 | $6.36M | +104.6% | -25.1% |
| Shares Outstanding | September 30, 2025 | 42.97M | -6.9% | -4.3% |
- Pacira BioSciences, Inc. reported Total Revenue of $726.41 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +3.6% in Total Revenue compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Revenue (ASC 606) of $726.41 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +3.6% in Revenue (ASC 606) compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Net Income of $7.03 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +107.1% in Net Income compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Diluted EPS of $0.16 per share for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +107.4% in Diluted EPS compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Total Assets of $1.26 billion for fiscal year 2025.
- Pacira BioSciences, Inc. showed a decrease of -18.6% in Total Assets compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Cash and Equivalents of $158.54 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed a decrease of -42.7% in Cash and Equivalents compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Long-Term Debt of $372.19 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed a decrease of -3.0% in Long-Term Debt compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Stockholders Equity of $693.11 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed a decrease of -11.0% in Stockholders Equity compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported R&D Expense of $117.31 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +43.8% in R&D Expense compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Operating Income of $19.19 million for fiscal year 2025.
- Pacira BioSciences, Inc. showed an increase of +126.2% in Operating Income compared to the prior fiscal year.
- Pacira BioSciences, Inc. reported Shares Outstanding of 41.12 million shares for fiscal year 2025.
- Pacira BioSciences, Inc. showed a decrease of -11.1% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: